United States· US:0173-0527_4492fd3c-e068-4599-8a10-0b26ea2a4f91
LAMICTAL
A lamotrigine product containing lamotrigine, registered in United States by GlaxoSmithKline LLC. The same ATC class is registered in 18 of our 19 countries.
Checked against FDA National Drug Code directory (United States) on
Informational only — not a medical device.
Where it is registered
Lamotrigine is registered in 18 of 19 countries.
Countries holding a registration under ATC N03AX09 (lamotrigine), each read from that country’s own register.
- This record: United States, from FDA National Drug Code directory (United States)
- 10 of them publish a price we can compare per daily dose
Lamotrigine · ATC N03AX09
18 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Germany
- Icelandprice
- Ireland
- Italyprice
- Japan
- Netherlands
- Norwayprice
- Polandprice
- Sweden
- Switzerlandprice
- United Kingdom
- United Statesprice
Price per daily dose
What a daily dose of lamotrigine costs, country by country.
Normalised to the WHO defined daily dose (0.3 g), the median price runs from $0.14 in United States to $4.21 in Switzerland — a ×30 gap.
- United States: $0.14 per daily dose (median across products in the class)
- Public list prices, converted to USD at the rate date shown
- US figures are pharmacy acquisition cost (CMS NADAC), not retail
Lamotrigine · price per daily dose (0.3 g)
USD · FX 28 Sept 2026
- CH Switzerland$4.21
- IT Italy$2.00
- FR France$1.69
- US United States$0.14 (acquisition cost)
The record
At a glance
FDA National Drug Code directory (United States)- Active substance
- LAMOTRIGINE
- Manufacturer
- GlaxoSmithKline LLC
- Country
- United States (US)
- ATC code
- N03AX09
- ATC class
- Lamotrigine
- Defined daily dose
- 0.3 g, O
- Reimbursed
- Not published by this register
- Source register
- FDA National Drug Code directory (United States)
- Last checked
- August 23, 2026
Packs & prices · 2
- ndc110173-0527-00
- ndc110173052700100 TABLET, FOR SUSPENSION in 1 BOTTLE (0173-0527-00)
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
248 interactions on record for lamotrigine.
Graded by severity as the source publishes them — 68 moderate. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Lamotrigine · interactions on record
248 records
- 68 moderate
- 9 minor
- 129 info
Most severe, free to view
- MetoclopramideA03FA01moderate
- DiphenhydraminA04AB05moderate
- DronabinolA04AD10moderate
- NabiloneA04AD11moderate
42 more interactions with mechanism and management, from a commercially licensed source.
Sign in to check- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Lamotrigine in 16 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- United KingdomLamictal 25mg dispersible tabletsWaymade Healthcare Plc
- FinlandLamoginestadSTADA Arzneimittel AG
- BelgiumLambipol 25 mgGlaxoSmithKline Pharmaceuticals
- ItalyAMALESSAUROBINDO PHARMA ITALIA S.R.L.
- NetherlandsLamotrigine Aurobindo 25 mg, dispergeerbare tablettenAurobindo Pharma B.V.
- SwedenLamotrigin Actavis 25 mg Dispergerbar tablettActavis Group PTC ehf.
- FranceLAMOTRIGINE BIOGARAN 25 mg, comprimé dispersibleBIOGARAN
- SpainLAMOTRIGINA STADA 25 mg COMPRIMIDOS DISPERSABLES EFGLaboratorio Stada S.L.
Authorised across Europe · EMA
The same active substance is authorised in 30 EEA countries. Names it is sold under:
- Austria · Gerolamic, Lamictal
- Belgium · Lambipol, Lamictal
- Bulgaria · Епитрижин, Ламиктал
- Cyprus · Lamictal, Lamosynt
- Czechia · Lamictal, Lamotrigin Actavis
- Germany · Lamictal, Lamotrigin 1 A Pharma
- Denmark · Lamictal, Lamotrigin
- Estonia · Lamictal, Lamotrigine Desitin
- Spain · Crisomet, Labileno
- Finland · Lamictal, Lamotrigin Desitin
- France · Lamictal, Lamotrigine
- United Kingdom (Northern Ireland) · Lamictal, Lamotrigine
- Greece · Dezepil, Lamictal
- Croatia · Arvind, Lamal
- Hungary · Gerolamic, Lamictal
- Ireland · Lamictal, Lamotrigine Desitin
- Iceland · Lamictal
- Italy · Amaless, Lamictal
- Lithuania · Lamictal
- Luxembourg · Lambipol, Lamictal
- Latvia · Lamictal, Lamotrix
- Malta · Lamictal, Lamotrigine Aurobindo
- Netherlands · Lambipol, Lamictal
- Norway · Lamictal, Lamotrigin Desitin
- Poland · Epitrigine, Lamilept
- Portugal · Lamictal, Lamotrigina Accord
- Romania · Lamictal, Lamotrix
- Sweden · Lamictal, Lamotrigin
- Slovenia · Lamal, Lamictal
- Slovakia · Lamictal, Lamotrigin Actavis
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of FDA National Drug Code directory (United States). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/a9f87de3-6b85-409a-9bf2-8ee168abaf37 GET /v1/drugs/a9f87de3-6b85-409a-9bf2-8ee168abaf37?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"route": "ORAL",
"source": "ndc",
"strength": "25",
"substance": "LAMOTRIGINE",
"productndc": "0173-0527",
"dosage_form": "TABLET, FOR SUSPENSION",
"dea_schedule": null,
"strength_unit": "mg/1",
"application_number": "NDA020764",
"marketing_category": "NDA"
}See everything about lamotrigine.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.